Allogene Frustrated By FDA’s Delayed CAR-T Trial Review

ALLO-510A Awaits Green Light To Start Phase II Study

 
• By Andrew McConaghie
  
Allogene building
Allogene wants to maintain its lead in the allo CAR-T field, but is facing a slow decision-making on its lead candidate. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip